Posted by Michael Wonder on 17 Sep 2025
Corstasis Therapeutics announces FDA approval of Enbumyst (bumetanide nasal spray) for the treatment of oedema associated with congestive heart failure, liver disease and kidney disease
15 September 2025 - Enbumyst is the first and only intranasal loop diuretic approved in the US offering a self-administered alternative between oral and intravenous diuretics.
Corstasis Therapeutics today announced that the US FDA has approved Enbumyst (bumetanide nasal spray). Enbumyst is indicated for the treatment of oedema associated with congestive heart failure, and hepatic and renal disease, including nephrotic syndrome in adults.
